1 – 20 of 21
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2019
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
- 2017
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
-
Mark
Long term azathioprine maintenance therapy in ANCA-associated vasculitis : combined results of long-term follow-up data
(
- Contribution to journal › Article
- 2015
-
Mark
The long-term outcomes of systemic vasculitis.
(
- Contribution to journal › Scientific review
-
Mark
Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
(
- Contribution to journal › Article
-
Mark
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
(
- Contribution to journal › Article
- 2014
-
Mark
Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
- 2013
-
Mark
Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al Reply
(
- Contribution to journal › Letter
-
Mark
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
(
- Contribution to journal › Article
- 2012
-
Mark
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
- 2011
-
Mark
Long-term patient survival in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
(
- Contribution to journal › Article
-
Mark
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
(
- Contribution to journal › Article
-
Mark
A Model to Predict Cardiovascular Events in Patients With Newly Diagnosed Wegener's Granulomatosis and Microscopic Polyangiitis
(
- Contribution to journal › Article
- 2009
-
Mark
Predictors of long-term (>= 5 year) renal survival in 535 patients with ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-term survival of ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Cardiovascular outcomes in ANCA associated vasculitis
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.848-848(
- Contribution to journal › Published meeting abstract